SCHEMBL15344932

SCHEMBL15344932

Cc1ccnc(-c2ccc3nc(N)ccc3c2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 13/20 0.60
NCK1 P16333 1/20 0.60
CTSD P07339 1/20 0.52
CCR1 P32246 1/20 0.47
CCR5 P51681 1/20 0.47
CCR8 P51685 1/20 0.47
PLAU P00749 1/20 0.46
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
NOS3 P29474 1/20 0.44
NOS1 P29475 1/20 0.44
NOS2 P35228 1/20 0.44
KMT2A Q03164 1/20 0.44
NCF1 P14598 2/20 0.44
CYP2A6 P11509 1/20 0.43
PIK3CD O00329 1/20 0.43
ABL1 P00519 1/20 0.43
EGFR P00533 1/20 0.43
HCK P08631 1/20 0.43
SRC P12931 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7229411 0.88 BACE1 (0.47) BACE1NCK1CTSDCCR1CCR5
SCHEMBL15341749 0.81 BACE1 (0.48) BACE1NCK1CTSDPLAUNCF1
SCHEMBL15344931 0.81 CCR1 (0.46) BACE1NCK1CCR1CCR5CCR8
SCHEMBL27960700 0.81 CCR1 (0.46) BACE1NCK1CCR1CCR5CCR8
SCHEMBL15344999 0.79 HPGD (0.46) CCR1CCR5CCR8MEN1KMT2A
SCHEMBL27960667 0.79 BACE1 (0.60) BACE1NCK1CTSDCCR1CCR5
Hydrochloric Acid SCHEMBL7240078 0.77 CCR1 (0.44) BACE1NCK1CCR1CCR5CCR8
SCHEMBL7048523 0.76 BACE1 (1.00) BACE1NCK1CTSDPLAUKDM4E
SCHEMBL15345083 0.76 BACE1 (0.52) BACE1NCK1CTSDPLAUKDM4E
SCHEMBL16805027 0.76 CCR1 (0.55) CCR1CCR5CCR8KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102574835-B Compounds for the treatment of cancer SPLICOS SOC 2014-04-16 CN claimed
EP-3070081-B1 BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION GILEAD SCIENCES INC (US) 2018-02-28 EP disclosed
US-20160015690-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-01-21 US disclosed
US-8987250-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-03-24 US disclosed
CN-103948594-A Compounds for the treatment of cancer SPLICOS SOC 2014-07-30 CN disclosed
CN-102574835-B Compounds for the treatment of cancer SPLICOS SOC 2014-04-16 CN disclosed
US-20130281433-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160015690-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 BACE1 386/4885NCK1 937/4885CTSD 1314/4885
US-20130281433-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 BACE1 386/4885NCK1 937/4885CTSD 1314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.